Axsome Therapeutics, Inc. (AXSM) Q2 FY26 Earnings Call

Commercial momentum accelerated, but Alzheimer's launch data remain early and profitability still depends on operating leverage.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-10
Length49 minutes
EPS$-0.99
EPS consensus$-0.99
Revenue$218.4M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25 · Q2 FY25

All AXSM earnings · Back to AXSM overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.